ARA-290

ARA‑290 (Cibinetide) – Innate Repair Receptor Peptide

ARA‑290, also known as cibinetide, is an 11‑amino‑acid peptide engineered from a specific tissue‑protective region of erythropoietin (EPO). It was designed to selectively activate the innate repair receptor (IRR) complex, allowing researchers to study anti‑inflammatory, tissue‑protective, and neuroprotective signaling pathways without the erythropoietic effects associated with full‑length EPO.

Key features

• Targeted EPO‑derived design: ARA‑290 mimics a receptor‑specific region of EPO that engages the IRR to drive cell‑protective signaling, while avoiding activation of the classical EPO receptor responsible for red‑blood‑cell production.

• Inflammation and tissue‑protection focus: Preclinical and clinical work suggests ARA‑290 can reduce inflammatory signaling, limit tissue injury, and promote repair across multiple organ systems.

• Neuroprotection and neuropathic models: Studied in small‑fiber neuropathy, diabetic neuropathy, and toxic or ischemic nerve‑injury models for its potential to improve nerve‑fiber measures and neuropathic pain scores.

• Non‑erythropoietic profile: Unlike native EPO, ARA‑290 does not significantly stimulate erythropoiesis at studied doses, enabling investigation of EPO‑like tissue protection with a distinct safety and mechanistic profile.

  
  

Research applications

ARA‑290 is used in experimental models exploring:

• Chronic inflammation and immune‑mediated tissue stress, including IRR‑mediated modulation of cytokines, microglial activation, and inflammasome signaling.

• Neuropathic pain and small‑fiber neuropathy, with studies reporting changes in corneal nerve fiber density, pain scores, and nerve‑fiber morphology.

• Neuroprotection in toxic and ischemic injury models, where ARA‑290 has been shown to reduce oxidative stress, apoptosis, and pro‑inflammatory markers while enhancing survival signaling.

  
  

Recommended handling

• For controlled laboratory research use only, by qualified professionals.

• Store in a cool, dry environment away from light; follow institutional SOPs for peptide storage, reconstitution, aliquoting, and disposal.

• Consult current literature when designing dosing regimens, timing, and outcome measures appropriate to each model.

  
  

Important disclaimer

All compounds sold by Rocky Peptide Chain, including ARA‑290, are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding clinical efficacy, symptom relief, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.